Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Details

reported its financial results for the fourth quarter and full-year 2024 on February 19, 2025. For the quarter, the company reported revenue of $1.00 billion, a GAAP loss per share of $(4.22), and non-GAAP earnings per share of $2.66. For the full year, revenue was $4.05 billion, GAAP earnings per share were $0.20, and non-GAAP earnings per share were $10.32. The company provided 2025 guidance and announced plans to repurchase approximately $350 million in common stock.

Items reported

Exhibits (1)

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.